Anzeige
Mehr »
Login
Dienstag, 21.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Aktienchance des Jahres! Ihre Chance auf explosive Gewinne!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0NBLH | ISIN: DK0060094928 | Ticker-Symbol: D2G
Tradegate
20.01.25
21:59 Uhr
39,050 Euro
+0,100
+0,26 %
1-Jahres-Chart
ORSTED A/S Chart 1 Jahr
5-Tage-Chart
ORSTED A/S 5-Tage-Chart
RealtimeGeldBriefZeit
38,68039,22020.01.
38,71039,19020.01.
Dow Jones News
475 Leser
Artikel bewerten:
(2)

Ørsted announces impairments relating to US interest rate increases, value of seabed leases, and execution of Sunrise Wind. 2024 EBITDA excluding new partnership agreements and cancellation fees of DKK 24.8 billion, in line with ...

Finanznachrichten News

DJ Ørsted announces impairments relating to US interest rate increases, value of seabed leases, and execution of Sunrise Wind. 2024 EBITDA excluding new partnership agreements and cancellation fees of DKK 24.8 billion, in line with guidance

Ørsted A/S (Orsted) 
Ørsted announces impairments relating to US interest rate increases, value of seabed leases, and execution of Sunrise 
Wind. 2024 EBITDA excluding new partnership agreements and cancellation fees of DKK 24.8 billion, in line with guidance 
20-Jan-2025 / 20:08 CET/CEST 
=---------------------------------------------------------------------------------------------------------------------- 
20.1.2025 20:08:00 CET | Ørsted A/S | Inside information 
Ørsted presents an operating profit (EBITDA) for 2024 based on preliminary and unaudited reporting. EBITDA excluding 
new partnership agreements and cancellation fees is expected to total DKK 24.8 billion in 2024, in line with the latest 
guidance. The operational earnings from Offshore and Onshore were the main contributors and delivered in line with our 
expectations. 
During Q4 2024, the development of the long-dated US interest rates led to a 75-basis-point increase in the weighted 
average cost of capital. This increase adversely impacted the value-in-use for the US portfolio, primarily the offshore 
wind projects, leading to an impairment of DKK 4.3 billion in Q4 2024. 
Market-informed valuation indications for our seabed leases located off the coasts of New Jersey, Maryland, and 
Delaware, which reflect prevailing market uncertainties among other factors, lead to an impairment of DKK 3.5 billion 
in Q4 2024. While this impairment substantially reduces the book value of the seabed leases, we believe the leases 
continue to hold strategic optionality and value, based on the long-term potential of the US offshore market. 
The Sunrise Wind project is progressing on a tight construction schedule and is navigating challenges related to supply 
chain and construction. The project follows on from Revolution Wind, which is currently under construction, including 
offshore installation work. Implementing learnings from Revolution Wind, such as the wind turbine installation rate, 
has led to a reassessment of the Sunrise Wind project to include schedule delays and increased costs. Additionally, we 
have updated our installation expectations for the first-ever US offshore HVDC system, including finalisation and 
installation of the jacket and export cables. The expected commissioning of the project has consequently been delayed 
into the second half of 2027. These developments, combined with considerably increased project costs relating 
especially to the monopile foundations to keep fabrication and installation on track, have led to higher cost 
expectations related to the execution of the Sunrise Wind project. The delayed commissioning and higher expected 
project costs will lead to an impairment of DKK 4.3 billion in Q4 2024. 
The developments relating to the interest rate increase, seabed leases, and the execution of Sunrise Wind, will, in 
aggregate, result in a DKK 12.1 billion impairment in Q4 2024. 
Mads Nipper, Group President and CEO of Ørsted, says: 
"The impairments announced today, and especially the continued construction challenges, are very disappointing. We are, 
however, encouraged by the performance of our operations, and we're confirming our full-year EBITDA guidance, supported 
by the increasing power production from our growing global fleet of renewable energy assets. 
"We remain committed to the US market in the long term with its potential for renewables to meet the growing 
electricity demand and create thousands of industrial jobs across the US. We continue to navigate the complexities and 
uncertainties we face in a nascent offshore industry in the new US market. Our dedicated efforts to strengthen 
execution and navigate supply chain challenges will continue. We're working diligently and in close collaboration with 
our suppliers to manage the remaining risks impacting the construction of Sunrise Wind. Delivering the project within 
the updated schedule and cost is an absolute top priority for Ørsted. 
"Including these adverse developments, the Sunrise Wind project is still profitable with a mid-single-digit lifecycle 
IRR and an attractive forward-looking IRR based on current assumptions. With enough offshore wind energy to power 
nearly 600,000 domestic homes, Sunrise Wind will create hundreds of long-term US-based jobs and build a statewide 
renewable energy economy that will energise New York for decades to come." 
Investor and analyst call 
In connection with the announcement of the impairments and preliminary and unaudited EBITDA for 2024, a call for 
investors and analysts will be held on 21 January 2025 at 08:00 CET. 
The investor and analyst call can be followed live at https://getvisualtv.net/stream/?orsted-update-hpvawfblmk. 
Presentation slides will be available after the call at: Annual reports and presentations | Ørsted 
Ørsted will publish its annual report for 2024 on Thursday, 6 February 2025. 
For further information, please contact: 
Media Relations 
Lina Danstrup 
+45 99 55 76 96 
lidan@orsted.com 
Investor Relations 
Rasmus Keglberg Hærvig 
+45 99 55 90 95 
ir@orsted.com 
About Ørsted 
The Ørsted vision is a world that runs entirely on green energy. Ørsted develops, constructs, and operates offshore and 
onshore wind farms, solar farms, energy storage facilities, renewable hydrogen and green fuels facilities, and 
bioenergy plants. Ørsted is recognised on the CDP Climate Change A List as a global leader on climate action and was 
the first energy company in the world to have its science-based net-zero emissions target validated by the Science 
Based Targets initiative (SBTi). Headquartered in Denmark, Ørsted employs approx. 8,400 people. Ørsted's shares are 
listed on Nasdaq Copenhagen (Orsted). In 2023, the group's revenue was DKK 79.3 billion (EUR 10.6 billion). Visit 
orsted.com or follow us on Facebook, LinkedIn, Instagram, and X. 
Attachments 
 . Ørsted CA no. 01 2025.pdf 
News Source: Ørsted A/S 
=---------------------------------------------------------------------------------------------------------------------- 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
ISIN:      DK0060094928 
Category Code: MSCM 
TIDM:      Orsted 
Sequence No.:  371657 
EQS News ID:  2071217 
 
End of Announcement EQS News Service 
=------------------------------------------------------------------------------------
 

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2071217&application_name=news&site_id=dow_jones%7e%7e%7ef1066a31-ca00-4e1a-b0a4-374bd7d0face

(END) Dow Jones Newswires

January 20, 2025 14:08 ET (19:08 GMT)

© 2025 Dow Jones News
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.